First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
The GLP-1 segment accounts for 15% of total diabetes
care market value in North America
Slide 67
North America GLP-1 market
GLP-1 value
in bDKK
VictozaⓇ
dulaglutide
OzempicⓇ
other
exenatide
Share of total
diabetes care
.
60
market
14%
Key observations for Victoza® in the US market
VictozaⓇ value market share within the GLP-1 segment is
54%¹
50
12%
CAGR value¹: 38.0%
Around 80% of Commercial and around 90% of Medicare
Part D GLP-1 market volume is covered without restrictions²
10%
40
8%
30
. Around 93% of new patients who start on VictozaⓇ
transition from outside of GLP-1 segment³
6%
20
4%
•
10
2%
Around 71% of prescriptions are for the higher dose 1.8
mg4
0
0%
Feb
Feb
2013
2018
1 CAGR for 5-year period
Source: IQVIA monthly MAT Feb, 2018 value figures (DKK)
changing
diabetes
Source: IQVIA NSP monthly, MAT Feb 2018
FingerTip Formulary bridge/ February 2018 Nomenclature and Xponent PlanTrak using week-ending 2
March 2018; only considers bridged volume; excludes cash and mail order data;
1.
2.
3.
IQVIA SOB, week ending 23 March 2018
4.
IQVIA weekly NPA, week ending 30 March 2018
novo nordiskView entire presentation